Thromb Haemost 2004; 92(06): 1291-1295
DOI: 10.1160/TH04-07-0409
Blood Coagulation, Fibrinolysis and Cellular Haemostasis
Schattauer GmbH

Hypofibrinogenaemia associated with a novel heterozygous γ289 Ala→Val substitution (fibrinogen Dorfen)

Amy Dear
1   Molecular Pathology Laboratory, Christchurch School of Medicine and Health Sciences, University of Otago, Christchurch, New Zealand
,
Stephen O. Brennan
1   Molecular Pathology Laboratory, Christchurch School of Medicine and Health Sciences, University of Otago, Christchurch, New Zealand
,
Carl-Erik Dempfle
2   First Department of Medicine, University Hospital of Mannheim, Mannheim, Germany
,
Werner Kirschstein
2   First Department of Medicine, University Hospital of Mannheim, Mannheim, Germany
,
Peter M. George
1   Molecular Pathology Laboratory, Christchurch School of Medicine and Health Sciences, University of Otago, Christchurch, New Zealand
› Institutsangaben
Weitere Informationen

Publikationsverlauf

Received 05. Juli 2004

Accepted after revision 26. September 2004

Publikationsdatum:
02. Dezember 2017 (online)

Preview

Summary

The molecular basis of hypofibrinogenaemia was investigated in a 34-year-old woman and her 10-year-old daughter. DNA sequencing revealed a single heterozygous GCC→GTC transition in exon 8 of the fibrinogen γ gene in both subjects, predicting a novel γ289 Ala→Val substitution. Examination of fibrinogen γ chains by electrospray ionization mass spectrometry failed to detect the variant chain in plasma fibrinogen. Further evidence for its non-expression came from tryptic peptide mapping. The mutation predicts a mass increase of 28 Da in peptide T32, but only the normal (M+2H) ion was detected at 1418 m/z in the proposita. Our finding that γ289 is an important determinant of plasma fibrinogen levels highlights the role of mutational analysis in defining structurally important regions of the fibrinogen molecule. This case suggests that the highly conserved Ala289 is important in maintaining structure of the “a” polymerization site via hydrogen bonding to Thr371.